文献速递神经免疫

奥法妥木单抗治疗抗N-甲基-D-天冬氨酸受体自身免疫性脑炎的疗效与安全性(OFF-AE):一项前瞻性、多中心队列研究

Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study.
PubMed 文献 · Ann Neurol · 2025-02-24

这项前瞻性多中心巢式队列研究基于CHASE注册研究,比较接受与未接受奥法妥木单抗治疗的NMDAR-AE患者,经倾向性评分匹配后每组58例。在未通过一线免疫治疗的患者中,奥法妥木单抗组末次随访时良好功能结局比例更高(87.9% vs 64.7%,OR 3.95,95%CI 1.12-13.94,p=0.026),且未报告与奥法妥木单抗相关的严重不良事件。

要点

  • 匹配后奥法妥木单抗组54例(93.1%)在启动后中位14天mRS评分进一步改善。
  • 一线免疫治疗失败者中奥法妥木单抗组良好功能结局87.9% vs 非奥法妥木单抗组64.7%(OR 3.95,95%CI 1.12-13.94,p=0.026)。
  • 未报告与奥法妥木单抗治疗相关的严重不良事件。

核心结论

  • 奥法妥木单抗显示出显著疗效和安全性,尤其在一线免疫治疗失败的患者中,值得在NMDAR-AE管理中考虑。

研究设计与样本

  • 前瞻性、多中心、巢式队列研究,比较2011年10月至2024年2月期间从CHASE注册研究招募的接受与未接受奥法妥木单抗治疗的NMDAR-AE患者,并进行倾向性评分匹配以平衡主要混杂因素。

主要发现

  • 共筛查715例AE患者,经倾向性评分匹配后奥法妥木单抗组和非奥法妥木单抗组各58例NMDAR-AE患者纳入分析。
  • 奥法妥木单抗组54例(93.1%)在启动奥法妥木单抗后中位14天mRS评分进一步改善,53例(91.4%)在末次随访时达到良好功能结局。
  • 对于一线免疫治疗失败的患者,奥法妥木单抗组较非奥法妥木单抗组mRS评分和CASE评分改善更快,且末次随访时更常达到良好功能结局(87.9% vs 64.7%,OR 3.95,95%CI 1.12-13.94,p=0.026)。
  • 未报告与奥法妥木单抗治疗相关的严重不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Ofatumumab presents a potentially promising alternative to current second-line immunotherapy for refractory anti-N-methyl-D-aspartate receptor autoimmune encephalitis (NMDAR-AE). We aimed to evaluate the efficacy and safety of ofatumumab as a novel second-line immunotherapy for NMDAR-AE. METHODS: This prospective, multicenter, nested cohort study compared patients with NMDAR-AE from the CHina Autoimmune encephalitiS outcomE study registry (CHASE) recruited between October 2011 and February 2024, treated with and without ofatumumab. The primary outcome was the proportion reaching a favorable functional outcome (modified Rankin Scale [mRS] score ≤2) at the last follow-up. Secondary outcomes included mRS scores and Clinical Assessment Scale in Autoimmune Encephalitis (CASE) scores over the first 24-month follow-up and the proportion with further mRS score improvement after ofatumumab initiation. A propensity score matching was performed to balance major confounders. RESULTS: A total of 715 patients with AE were screened. Fifty-eight propensity score-matched patients with NMDAR-AE each in the ofatumumab group and non-ofatumumab group were analyzed. Fifty-four patients (93.1%) in the ofatumumab group achieved further mRS score improvement with a median time of 14 days from ofatumumab initiation, and 53 (91.4%) reached a favorable functional outcome at the last follow-up. For those who failed first-line immunotherapy, the ofatumumab group demonstrated a faster mRS score and CASE score improvement and more frequently reached a favorable functional outcome at the last follow-up compared with the non-ofatumumab group (87.9% vs. 64.7%, odds ratio [OR] 3.95; 95% confidence interval [CI] 1.12-13.94; p = 0.026). No serious adverse events associated with ofatumumab treatment were reported. INTERPRETATION: Ofatumumab showed substantial efficacy and safety, particularly in patients who failed first-line immunotherapy, warranting its consideration in NMDAR-AE management. ANN NEUROL 2025;98:80-92.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Guo K, Peng F, Liu J, et al. Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study. Ann Neurol. 2025. PMID: 39991981. doi:10.1002/ana.27218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。